CLINICAL_TRIALS
trial_result
· 2019-03-08
Clinical Trial Update: A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer [Phase 3]
Summary
Phase 3 trial evaluating ramucirumab plus docetaxel in urothelial carcinoma has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Urothelial Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2019-03-08